Evidence map›Paper›PMID 30464632›Full record

ArticleCancer management and research2018

Chemotherapy combined with dendritic cell vaccine and cytokine-induced killer cells in the treatment of colorectal carcinoma: a meta-analysis.

Xiuling Zhou, Xiangqiong Mo, Junlan Qiu, Jingjing Zhao, Shuncong Wang, Cuiling Zhou, Yonghui Su, Zhong Lin, Haiqing Ma

Open access · goldAbstract read
In one paragraph

Article in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. PIKfyve controls dendritic cell function and tumor immunity.bioRxiv : the preprint server for biology · 2024
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Xiuling ZhouDepartment of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China, mahaiqing@mail.sysu.edu.cn; linzhong123@163.com.
Xiangqiong MoDepartment of General Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China.
Junlan QiuDepartment of Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Science & Technology Town Hospital, Jiangsu 215153, China.
Jingjing ZhaoDepartment of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Shuncong WangDepartment of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China, mahaiqing@mail.sysu.edu.cn; linzhong123@163.com.
Cuiling ZhouDepartment of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China, mahaiqing@mail.sysu.edu.cn; linzhong123@163.com.
Yonghui SuDepartment of General Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China.
Zhong LinDepartment of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China, mahaiqing@mail.sysu.edu.cn; linzhong123@163.com.
Haiqing MaDepartment of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, China, mahaiqing@mail.sysu.edu.cn; linzhong123@163.com.
Fifth Affiliated Hospital of Sun Yat-sen University · CNSun Yat-sen University · CNNanjing Medical University · CNSun Yat-sen University Cancer Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the efficacy and safety of dendritic cell (DC) vaccine combined with cytokine-induced killer (CIK) cell therapy in colorectal carcinoma (CRC). PATIENTS AND

methodsPubMed, Embase, and Cochrane Library databases were searched systematically for clinical trials of DC vaccine and CIK cell therapy combined with chemotherapy for CRC. The primary and secondary endpoints were overall survival (OS) and disease-free survival (DFS), respectively. Pooled risk ratios were used to assess the treatment efficacy. Both random and fixed effects models were used for statistical analysis. The study population consisted of 871 CRC patients enrolled in four trials.

resultsOS and DFS were significantly improved in patients who received chemotherapy combined with DC vaccine and CIK cells, and no severe adverse events were shown.

conclusionsThe study demonstrated that the addition of DC vaccine and CIK cell therapy to chemotherapy is feasible and effective in patients with CRC.

Indexed as

adoptive cellular therapycolorectal carcinomacytokine-induced killer celldendritic cell vaccinedisease-free survivalimmunotherapyoverall survival

Identifiers

PMID30464632
PMCPMC6225919
OpenAlexW2898762613

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.